Trial Profile

A phase I dose escalation study of intravesical TMX-101 in subjects with Non-Muscle-Invasive Bladder Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 26 Aug 2013

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imiquimod (Primary)
Indications Bladder cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Telormedix

Most Recent Events

26 Aug 2013 New source identified and integrated (ISRCTN: Current Controlled Trials)
21 Aug 2013 Status changed from recruiting to completed, according to ISRCTN: Current Controlled Trials
10 Jan 2012 Telormedix received CHF7.5 million in financing, which in part, will be used to support this trial, according to a company media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com